Elixxer Ltd V.ELXR

Target 0,30$ end of 2019 and 0.75$ 2022 ? What do you think?

[BeachHouse1Day]

The Ubika Alpha report is interesting.

There are a lot of ''IF'' with this company.

In the 2018 year in review they mentioned:
"The aggressive investment strategy adopted by LGC in 2018 has positioned LGC as a recognized global leader and as such we are now being approached by numerous potential strategic partners wanting to align with us.
We believe that this coming year will see our investee companies announce many supply agreements, expand their growing
operations and ultimately accelerate revenue and profits. We also envisage a number of investee companies getting listed on various stock exchanges.''

You would think a bigger strategic partner would have submitted to Global Canna Labs an offer for lets say 30% of the company for a certain amount of money or shares in that company. For example some of deals that Aurora has done given a certain amount for a portion of a company and if certain goals are reached they would pay a higher amount for a bigger part in that company. You would think that Global Canna Labs would receive such an offer to accelerate growth. But nope they are planting a few hundred plants at a time and not maximizing the license they have. They have some short of deal with Sproutly but there are not a lot of details out there.

With the multiples going around for Pot companies and future production targets LGC Capital should be closer to a price target of 0.30$ by the end of the year or sooner but they seem to want to keep the price low until the ''Friendly' financial agreement for 8M shares at 0.10$ and a board seat is passed with Arlington Capital Inc. 

So much potential but little to show for until now.
Other companies seem to be pumping there stock  (ex: AGRA) but his one is trending down even if they keep mentioning in there releases ''..LGC presently will have interests in over 450,000 square feet of planted cannabis in Jamaica, Switzerland, Italy, and Australia. That is expected to increase to over 2,100,000 square feet by 2021, as its portfolio companies execute their expansion plans, in addition to the anticipated licensing of Tricho-Med's operations in Quebec, Canada.''.

With the production targets in the Ubika Alpha report would this stock have a potential target of 0.75$ to 1$ in 2022?
And that is not even including if Global Canna Labs, Little Green Pharma, Easyjoint and Viridi Unit SA have IPOs.